FDA editorial on breakthrough therapy designation and investment fund strategy

The passage is a routine editorial describing FDA policy and a private investment fund's focus. It contains no allegations, financial misconduct, or links to high‑profile officials beyond standard tit Janet Woodcock, MD, FDA CDRH director, co‑authored a NEJM editorial on breakthrough therapy designat Breakthrough therapy designation created under FDASIA in 2012; 26 designations granted on 80 reque